CorVivo

Focus: CorVivo is a cardiovascular-focused biotech company developing epicardial patch and extracellular matrix (ECM) based therapies for acute coronary syndrome, heart failure, and valvular diseases. The company operates as a pre-revenue stage biotech with a concentrated pipeline in regenerative cardiac repair.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CorVivo

AI assessmentNot Hiring

No open roles listed right now. Follow CorVivo to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

5 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CorMatrix Cor TRICUSPID ECM Valve

Tricuspid Valve Disease

N/A

Clinical Trials (1)

NCT02397668CorMatrix Cor TRICUSPID ECM Valve Replacement Study

N/A

Help build intelligence for CorVivo

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-unmet-need cardiovascular indications (ACS, heart failure, tricuspid valve disease) with multiple ECM-based programs
Early-stage opportunity to build expertise in regenerative medicine and implantable device-tissue hybrid technologies
Roswell, GA location offers lower cost-of-living alternative to major biotech hubs

Watch Out For

Pre-revenue, pre-Series funding stage with no disclosed funding or financial runway—typical of companies 3-5 years from major catalyst or acquisition
Only 1 Phase 1 program; majority of pipeline in preclinical/early development with minimal clinical validation data
Zero active job openings and no hiring activity on record suggests limited near-term growth or headcount expansion

Generated by Claude from CorVivo's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Tricuspid valve replacement with the Cor TRICUSPID ECM Valve

Tricuspid Valve Disease

N/A

Clinical Trials (1)

NCT05742906CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study

N/A

P-ECM Implant

Heart Failure

N/A

Clinical Trials (1)

NCT02139189Restore Myocardial Function With CorMatrix® ECM® Particulate (P-ECM)

N/A